A Randomized, Double-blind, Placebo-controlled, Two-period Crossover Study to Assess the Effect of Inhaled QVA149 on Global and Regional Lung Function and Gas Exchange in Patients With Moderate to Severe COPD
Phase of Trial: Phase III
Latest Information Update: 15 Sep 2017
At a glance
- Drugs Glycopyrrolate/indacaterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacodynamics
- Sponsors Novartis Pharmaceuticals Corporation
- 12 Sep 2017 Planned End Date changed from 1 Sep 2017 to 15 Nov 2017.
- 12 Sep 2017 Planned primary completion date changed from 1 Sep 2017 to 15 Nov 2017.
- 10 Aug 2016 Status changed from not yet recruiting to recruiting.